Sébastien Lacroix-Desmazes
Lacroix-Desmazes, Sébastien, 19..-...., chercheur en immunologie
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Lacroix-Desmazes, Sébastien
VIAF ID: 213326916 (Personal)
Permalink: http://viaf.org/viaf/213326916
Preferred Forms
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| ANALYSE DES REPERTOIRES AUTOREACTIFS DES ANTICORPS NATURELS CHEZ L'HOMME SAIN ET AU COURS DE PATHOLOGIES DYSIMMUNITAIRES |
|
| ANALYSIS OF SELF-REACTIVE REPERTOIRES OF NATURAL ANTIBODIES IN HEALTHY HUMAN AND DURING DYSIMMUNE DISEASES. |
|
| Anti-HLA antibodies in antibody-mediated rejection : role of IgG subclasses distribution and glycosylation. |
|
| Les anticorps anti-HLA au cours du rejet à médiation humorale : rôle de la sous-classe et de la glycosylation des anticorps |
|
| Anticorps catalytiques dirigés contre le FVIII dans différentes maladies chez l'homme |
|
| Caractérisation des mécanismes de présentation des antigènes par les molécules du CMH-II |
|
| Catalytic antibodies directed against factor VIII in different human disorders. |
|
| Characterization of MHC-II-restricted antigen presentation mechanisms. |
|
| Control of the immune response directed against the therapeutic factor FVIII. |
|
| Creating and Use of an New Experimental Preclinical HLA Transgenic Mice Model to Mapping HLA-restricted T Cells Epitopes for Polyepitopes Vaccine Design |
|
| Deciphering the early events leading to an adaptive immune response during urinary tract infection. |
|
| Définir le début des événements conduisant à une réponse immunitaire adaptative lors de l'infection urinaire |
|
| Eradication des inhibiteurs du FVIII chez les patients atteints d'hémophilie A. |
|
| Étude de l'implication de l'activateur tissulaire du plasminogène dans la réponse immunitaire |
|
| Exploitation d’un modèle expérimentale préclinique de souris HLA transgénique pour l’identification des épitopes T HLA-restreint afin de concevoir des vaccins poly-epitopiques. |
|
| A high-throughput selection system to quantify the specificity of antibodies |
|
| Identification des épitopes T d'ADAMTS13 chez les patients atteints de Purpura Thrombotique Thrombocytopénique |
|
| Immunogénicité du facteur VIII thérapeutique : importance du complément et des domaines C du facteur VIII pour son endocytose |
|
| Impact de l'IL-1β sur les lymphocytes Tfh et Tfr dans la réaction de centre germinatif physiologique et pathologique. |
|
| Influence of the polyreactivity natural and led by the soluble immunoglobulins and the receivers of lymphocytes B on the modulation of the immune response. |
|
| The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status |
|
| Intravenous immunoglobulin in neurological disorders: a mechanistic perspective |
|
| IVIg treatment reduces catalytic antibody titers of renal transplanted patients |
|
| Modulation of human dendritic cell maturation and function by natural IgG antibodies |
|
| Natural autoantibodies: immune homeostasis and therapeutic intervention |
|
| Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. |
|
| Natural recognition repertoire and the evolutionary emergence of the combinatorial immune system |
|
| Neutralization of Japanese Encephalitis Virus by heme-induced broadly reactive human monoclonal antibody |
|
| Noncanonical Functions of Antibodies |
|
| Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants |
|
| Novel therapeutic strategies for multiple sclerosis: potential of intravenous immunoglobulin |
|
| Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A. |
|
| Parameters that influence the prediction of epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnosis |
|
| Pathophysiology of inhibitors to factor VIII in patients with haemophilia A. |
|
| Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. |
|
| Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G. |
|
| Polyreactivity of disease-associated anti-RBC IgG autoantibodies of patients with warm autoimmune haemolytic anaemia and natural anti-RBC IgG autoantibodies of healthy individuals |
|
| Predictive immunogenicity of Refacto AF. |
|
| Prevalence and gene characteristics of antibodies with cofactor-induced HIV-1 specificity. |
|
| Proteolytic antibodies activate factor IX in patients with acquired hemophilia. |
|
| Receptor of endocytosis for factor VIII by antigen presenting cells and role in the initiation of anti factor VIII immune response |
|
| Red blood cell transfusions are associated with alterations in self-reactive antibody repertoires of plasma IgM and IgG, independent of the presence of a specific immune response toward RBC antigens |
|
| [Regulation of autoreactivity by the idiotypic network and therapeutic modulation of autoimmunity by polyvalent intravenous immunoglobulins (IgIV)] |
|
| Relationship between natural and heme-mediated antibody polyreactivity. |
|
| Rôle de l'environnement inflammatoire dans l'immunogénicité du facteur VIII thérapeutique chez les patients hémophiles A |
|
| A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes |
|
| Role of the intrinsic coagulation pathway in atherogenesis assessed in hemophilic apolipoprotein E knockout mice |
|
| The role of VWF in the immunogenicity of FVIII. |
|
| Rôle physiopathologique des anticorps catalytiques et des anticorps polyréactifs |
|
| Selective impairment of serum antibody repertoires toward muscle and thymus antigens in patients with seronegative and seropositive myasthenia gravis |
|
| The self-reactive antibody repertoire of normal human serum IgM is acquired in early childhood and remains conserved throughout life |
|
| Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin. |
|
| Les signaux de danger dans l'initiation de la réponse immunitaire contre le facteur VIII thérapeutique |
|
| Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium |
|
| Study of the implication of tissue-type plasminogen receptor in immune response. |
|
| Study of the response of human hormone H2-relaxin-specific T-cells and non-natural modifications : perspectives for the reduction of the immunogenicity of therapeutic proteins and peptides. |
|
| Summary report of the First International Conference on inhibitors in haemophilia A. |
|
| Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. |
|
| T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. |
|
| Therapeutic factor VIII does not trigger TLR1.2 and TLR2.6 signalling in vitro. |
|
| Therapeutic strategies against FVIII immune response in hemophilia A : by modifying FVIII structure, by inhibiting B cells signalisation. |
|
| Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor. |
|
| Thermodynamic stability contributes to immunoglobulin specificity |
|
| Transfert materno-foetal de protéines thérapeutiques par des IgGs modifiées et induction de tolérance immunitaire |
|
| Transition towards antigen-binding promiscuity of a monospecific antibody |
|
| Transplacental delivery of therapeutic proteins mediated by engineered IgGs and tolerance induction. |
|
| [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders]. |
|
| Vers le développement d'une thérapie génique pour la maladie de Pompe : Caractérisation du phénotype immunitaire de la maladie de Pompe et comparaison du potentiel thérapeutique de la thérapie génique avec le traitement standard actuel. |
|
| VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. |
|
